Basic and Clinical ImmunologyAllergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: Results of a phase I trial☆,☆☆
Section snippets
Methods
Sixteen patients hypersensitive to BV were recruited from the Outpatient Clinic of the Division of Allergy and Immunology, Lausanne, Switzerland (9 men, 7 women). All patients gave informed consent to the study, and study protocols were approved by the Hospital Review Board. Criteria for enrollment were grade I to IV systemic hypersensitivity reaction to honey bee field sting (according to Müller classification14), positive anti-PLA2 and anti-whole BV-specific IgE (>0.35 kU/L as titrated by CAP
Patient data
Patients were randomly assigned to the LSP or control (albumin) groups. In the LSP group, the mean age of patients was 39 ± 14 years (5 men, 4 women). One patient had a history of grade I hypersensitivity to BV, 7 had grade III, and 1 had grade IV, according to Müller classification. EPC for ID tests to BV was 10−1.7 μg/mL (geometric mean). Mean serum anti-BV-specific IgE level was 21.5 ± 33.9 kU/L. In the control group, the mean age was 40 ± 10 years (4 men, 3 women). One patient previously
Discussion
We have shown in this study that a peptide-based allergen immunotherapy with LSPs derived from PLA2, a major BV allergen, was able to induce T-cell anergy, immune deviation toward a TH1-type T-cell cytokine response, enhanced IL-10 secretion, and PLA2-specific IgG4 production. LSP immunotherapy was safe and did not induce severe systemic reactions, though dose cumulation appeared to induce mild, nonimmediate reactions in two patients.
The fact that LSPs could be injected without any local or
References (38)
- et al.
Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety
J Allergy Clin Immunol
(1992) - et al.
Modulation of T-cell response to phospholipase A2 and phospholipase A2-derived peptides by conventional bee venom immunotherapy
J Allergy Clin Immunol
(1997) - et al.
Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom
J Allergy Clin Immunol
(1998) - et al.
Antibody responses to bee melittin (Api m 4) and hornet antigen 5 (Dol m 5) in mice treated with the dominant T-cell epitope peptides
J Allergy Clin Immunol
(1998) - et al.
Type I skin reactivity to native and recombinant phospholipase A(2) from honeybee venom is similar
J Allergy Clin Immunol
(1995) - et al.
A simple and rapid procedure for the purification of synthetic polypeptides by a combination of affinity chromatography and methionine chemistry
FEBS Lett
(1997) - et al.
Hymenoptera venom immunotherapy, I: induction of T cell-mediated immunity by honeybee venom immunotherapy: relationships with specific antibody responses
J Allergy Clin Immunol
(1989) - et al.
Prognostic value of immunoblotting in patients on immunotherapy with hymenoptera venom
J Allergy Clin Immunol
(2000) - et al.
Ultrarush immunotherapy in patients with Hymenoptera venom allergy
J Allergy Clin Immunol
(2001) - et al.
Delineation of PLA(2) epitopes using short or long overlapping synthetic peptides: interest for specific immunotherapy
Clin Exp Allergy
(1997)
Treatment of cat allergy with T-cell reactive peptides
Am J Respir Crit Care Med
Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1
Clin Exp Immunol
Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I
Proc Natl Acad Sci U S A
T cell epitopes of house dust mite major allergen Der p II
J Immunol
Characterization of cat dander-specific T lymphocytes from atopic patients
J Immunol
Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects
J Immunol
Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis
Eur J Immunol
Diagnosis and treatment of insect sensitivity
J Asthma Res
Position paper: Immunotherapy with hymenoptera venoms
Allergy
Cited by (143)
Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season
2018, Journal of Allergy and Clinical ImmunologyEfficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study
2016, Journal of Allergy and Clinical ImmunologyCitation Excerpt :Considering the limited statistical power of the study, both dosages can be considered equivalent in efficacy, with no additional benefit from higher dose, as previously observed in another AIT study based on peptides.21 Long synthetic peptides appeared safe in several vaccine trials,22,23 as well as in 2 AIT trials based on COPs derived from phospholipase A2, the major allergen of bee venom, or from Bet v 1 in a recent phase I/IIa study.8,24 COPs were carefully selected among several sets of peptides, leading to the choice of Bet v 1 COPs, a set of 3 long synthetic peptides with the lowest IgE-binding capacity.7
Allergen Immunotherapy: Vaccine Modification
2016, Immunology and Allergy Clinics of North AmericaTherapeutic Approaches in Allergic Diseases
2016, Immune Rebalancing: The Future of ImmunosuppressionCharacterization of human memory CD4<sup>+</sup> T-cell responses to the dog allergen Can f 4
2015, Journal of Allergy and Clinical ImmunologyAssociation between specific timothy grass antigens and changes in T<inf>H</inf>1- and T<inf>H</inf>2-cell responses following specific immunotherapy
2014, Journal of Allergy and Clinical Immunology
- ☆
Supported by the CHUV/UNIL/EPFL Common Program in Medical Engineering and by the Swiss National Fund for Scientific Research no. 3100-059482.
- ☆☆
Reprint requests: Dr F. Spertini, Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon, Lausanne 1011, Switzerland.